Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Non small cell lung cancer · oligometastatic hormone sensitive prostate cancer · CERO

CERo Therapeutics

CERO THERAPEUTICS HOLDINGS, INC.

CERo Therapeutics patent portfolio — 14 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
201 Haskins Way, 230, South San Francisco, California 94080, US HQ
17 Employees
Public company Type
CERO · NYSE Ticker
Company details
Status
Public
HQ
201 Haskins Way, 230, South San Francisco, California 94080, US
Employees
17
Programs
47
Drugs
84
Patents
14
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

CERo Therapeutics patents

14 pharmaceutical patents indexed for CERo Therapeutics. 0 expire within 24 months.

CERo Therapeutics has 14 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

14 patents

Patent portfolio

  1. US 12303551

    Cellular immunotherapy compositions and uses thereof

    Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12291557

    Chimeric TIM4 receptors and uses thereof

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11708423

    Chimeric engulfment receptor molecules and methods of use

    Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11697689

    Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs

    Expires Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11655282

    Chimeric engulfment receptor molecules

    Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10675246

    Orally administrable compositions comprising calcium

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10307410

    Mcl-1 modulating compounds for cancer treatment

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10273307

    Humanized anti-CD134 (OX40) antibodies and uses thereof

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9790281

    Humanized anti-CD134 (OX40) antibodies and uses thereof

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9523691

    Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis

    Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9475880

    Anti-CD134 (OX40) antibodies and uses thereof

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9463193

    Individual 5-fluorouracile dose optimization in folfiri treatment

    Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8652516

    Doxycycline formulations, and methods of treating rosacea

    Expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 6495072

    Method for making basis for a dental restoration

    Expires Mon Dec 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many patents does CERo Therapeutics have?

14 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do CERo Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.